nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—Hydrocortisone—psoriasis	0.238	1	CrCtD
Medroxyprogesterone Acetate—breast cancer—Betamethasone—psoriasis	0.105	0.5	CpDpCtD
Medroxyprogesterone Acetate—breast cancer—Dexamethasone—psoriasis	0.105	0.5	CpDpCtD
Medroxyprogesterone Acetate—NR3C1—Clobetasol propionate—psoriasis	0.0304	0.136	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Fluocinolone Acetonide—psoriasis	0.0231	0.103	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Fluocinonide—psoriasis	0.0231	0.103	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Beclomethasone—psoriasis	0.0231	0.103	CbGbCtD
Medroxyprogesterone Acetate—PGR—Betamethasone—psoriasis	0.0154	0.0688	CbGbCtD
Medroxyprogesterone Acetate—SHBG—Hydrocortisone—psoriasis	0.0139	0.0618	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Triamcinolone—psoriasis	0.00919	0.041	CbGbCtD
Medroxyprogesterone Acetate—PGR—Dexamethasone—psoriasis	0.00898	0.04	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Tazarotene—psoriasis	0.00854	0.0381	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Betamethasone—psoriasis	0.00788	0.0351	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Prednisolone—psoriasis	0.00778	0.0347	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—Hydrocortisone—psoriasis	0.00737	0.0329	CbGbCtD
Medroxyprogesterone Acetate—Prednicarbate—Clobetasol propionate—psoriasis	0.00736	0.0293	CrCrCtD
Medroxyprogesterone Acetate—NR3C1—Prednisone—psoriasis	0.00734	0.0328	CbGbCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Clobetasol propionate—psoriasis	0.00676	0.027	CrCrCtD
Medroxyprogesterone Acetate—Flurandrenolide—Fluocinonide—psoriasis	0.0067	0.0267	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Clobetasol propionate—psoriasis	0.00659	0.0263	CrCrCtD
Medroxyprogesterone Acetate—Flurandrenolide—Fluocinolone Acetonide—psoriasis	0.00651	0.026	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortamate—Beclomethasone—psoriasis	0.00627	0.025	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Clobetasol propionate—psoriasis	0.00612	0.0244	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Beclomethasone—psoriasis	0.00589	0.0235	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Clobetasol propionate—psoriasis	0.00572	0.0228	CrCrCtD
Medroxyprogesterone Acetate—Eplerenone—Hydrocortisone—psoriasis	0.00553	0.0221	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Fluocinolone Acetonide—psoriasis	0.00513	0.0205	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Beclomethasone—psoriasis	0.0049	0.0195	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Fluocinonide—psoriasis	0.0049	0.0195	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Fluocinolone Acetonide—psoriasis	0.00476	0.019	CrCrCtD
Medroxyprogesterone Acetate—NR3C1—Dexamethasone—psoriasis	0.00458	0.0204	CbGbCtD
Medroxyprogesterone Acetate—Methylprednisolone—Fluocinonide—psoriasis	0.00458	0.0183	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Fluocinolone Acetonide—psoriasis	0.00445	0.0178	CrCrCtD
Medroxyprogesterone Acetate—Drospirenone—Hydrocortisone—psoriasis	0.0044	0.0175	CrCrCtD
Medroxyprogesterone Acetate—Dydrogesterone—Hydrocortisone—psoriasis	0.0044	0.0175	CrCrCtD
Medroxyprogesterone Acetate—Spironolactone—Hydrocortisone—psoriasis	0.00419	0.0167	CrCrCtD
Medroxyprogesterone Acetate—Potassium Canrenoate—Hydrocortisone—psoriasis	0.00419	0.0167	CrCrCtD
Medroxyprogesterone Acetate—Megestrol acetate—Hydrocortisone—psoriasis	0.00383	0.0153	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Cholecalciferol—psoriasis	0.00364	0.0163	CbGbCtD
Medroxyprogesterone Acetate—Potassium Canrenoate—Prednisone—psoriasis	0.00361	0.0144	CrCrCtD
Medroxyprogesterone Acetate—Medrysone—Hydrocortisone—psoriasis	0.00354	0.0141	CrCrCtD
Medroxyprogesterone Acetate—Potassium Canrenoate—Prednisolone—psoriasis	0.00352	0.014	CrCrCtD
Medroxyprogesterone Acetate—Flurandrenolide—Hydrocortisone—psoriasis	0.00329	0.0131	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Mycophenolate mofetil—psoriasis	0.00316	0.0141	CbGbCtD
Medroxyprogesterone Acetate—Hydrocortamate—Hydrocortisone—psoriasis	0.00308	0.0123	CrCrCtD
Medroxyprogesterone Acetate—Flurandrenolide—Dexamethasone—psoriasis	0.00305	0.0122	CrCrCtD
Medroxyprogesterone Acetate—Flurandrenolide—Betamethasone—psoriasis	0.00305	0.0122	CrCrCtD
Medroxyprogesterone Acetate—Cortisone acetate—Hydrocortisone—psoriasis	0.00298	0.0119	CrCrCtD
Medroxyprogesterone Acetate—Medrysone—Prednisolone—psoriasis	0.00297	0.0119	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Hydrocortisone—psoriasis	0.00289	0.0115	CrCrCtD
Medroxyprogesterone Acetate—CYP3A4—Calcitriol—psoriasis	0.00287	0.0128	CbGbCtD
Medroxyprogesterone Acetate—Flurandrenolide—Prednisolone—psoriasis	0.00276	0.011	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Dexamethasone—psoriasis	0.00269	0.0107	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Betamethasone—psoriasis	0.00269	0.0107	CrCrCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Hydrocortisone—psoriasis	0.00266	0.0106	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortamate—Prednisone—psoriasis	0.00265	0.0106	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Triamcinolone—psoriasis	0.00262	0.0105	CrCrCtD
Medroxyprogesterone Acetate—Testosterone Propionate—Hydrocortisone—psoriasis	0.00259	0.0103	CrCrCtD
Medroxyprogesterone Acetate—Progesterone—Hydrocortisone—psoriasis	0.00259	0.0103	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Hydrocortisone—psoriasis	0.00259	0.0103	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortamate—Prednisolone—psoriasis	0.00259	0.0103	CrCrCtD
Medroxyprogesterone Acetate—Cortisone acetate—Prednisone—psoriasis	0.00257	0.0102	CrCrCtD
Medroxyprogesterone Acetate—CYP2C9—Cholecalciferol—psoriasis	0.00254	0.0113	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Hydrocortisone—psoriasis	0.00254	0.0113	CbGbCtD
Medroxyprogesterone Acetate—Methyltestosterone—Hydrocortisone—psoriasis	0.00252	0.0101	CrCrCtD
Medroxyprogesterone Acetate—Cortisone acetate—Prednisolone—psoriasis	0.00251	0.00999	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Prednisone—psoriasis	0.00249	0.00993	CrCrCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Dexamethasone—psoriasis	0.00247	0.00985	CrCrCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Betamethasone—psoriasis	0.00247	0.00985	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Prednisolone—psoriasis	0.00243	0.0097	CrCrCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Triamcinolone—psoriasis	0.00241	0.00962	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Hydrocortisone—psoriasis	0.00241	0.00959	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Betamethasone—psoriasis	0.0024	0.00959	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Dexamethasone—psoriasis	0.0024	0.00959	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Cyclosporine—psoriasis	0.00239	0.0107	CbGbCtD
Medroxyprogesterone Acetate—Fludrocortisone—Triamcinolone—psoriasis	0.00235	0.00937	CrCrCtD
Medroxyprogesterone Acetate—Testosterone—Hydrocortisone—psoriasis	0.00225	0.00897	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Hydrocortisone—psoriasis	0.00225	0.00897	CrCrCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Prednisolone—psoriasis	0.00223	0.00891	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Betamethasone—psoriasis	0.00223	0.00891	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Dexamethasone—psoriasis	0.00223	0.00891	CrCrCtD
Medroxyprogesterone Acetate—CYP3A4—Methoxsalen—psoriasis	0.00223	0.00995	CbGbCtD
Medroxyprogesterone Acetate—Fludrocortisone—Prednisone—psoriasis	0.00223	0.00889	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Triamcinolone—psoriasis	0.00218	0.0087	CrCrCtD
Medroxyprogesterone Acetate—Progesterone—Prednisolone—psoriasis	0.00218	0.00868	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Prednisolone—psoriasis	0.00218	0.00868	CrCrCtD
Medroxyprogesterone Acetate—Methyltestosterone—Prednisone—psoriasis	0.00217	0.00867	CrCrCtD
Medroxyprogesterone Acetate—Methyltestosterone—Prednisolone—psoriasis	0.00212	0.00846	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Betamethasone—psoriasis	0.00209	0.00833	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Dexamethasone—psoriasis	0.00209	0.00833	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Prednisone—psoriasis	0.00207	0.00826	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Triamcinolone—psoriasis	0.00204	0.00814	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Prednisolone—psoriasis	0.00202	0.00806	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Dexamethasone—psoriasis	0.00196	0.00782	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Betamethasone—psoriasis	0.00196	0.00782	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Prednisone—psoriasis	0.00194	0.00772	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Triamcinolone—psoriasis	0.00192	0.00764	CrCrCtD
Medroxyprogesterone Acetate—Methylprednisolone—Prednisolone—psoriasis	0.00189	0.00754	CrCrCtD
Medroxyprogesterone Acetate—Testosterone—Prednisolone—psoriasis	0.00189	0.00754	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Prednisone—psoriasis	0.00182	0.00725	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Prednisolone—psoriasis	0.00178	0.00708	CrCrCtD
Medroxyprogesterone Acetate—CYP2C9—Cyclosporine—psoriasis	0.00167	0.00745	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Dexamethasone—psoriasis	0.00158	0.00703	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Cholecalciferol—psoriasis	0.00148	0.00659	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Mycophenolate mofetil—psoriasis	0.00128	0.00572	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Triamcinolone—psoriasis	0.00128	0.00572	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Dexamethasone—psoriasis	0.0011	0.00491	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Betamethasone—psoriasis	0.0011	0.0049	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Prednisolone—psoriasis	0.00108	0.00484	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Hydrocortisone—psoriasis	0.00103	0.00459	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Prednisone—psoriasis	0.00102	0.00457	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Cyclosporine—psoriasis	0.000971	0.00433	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Dexamethasone—psoriasis	0.00064	0.00285	CbGbCtD
Medroxyprogesterone Acetate—ESR1—Nuclear Receptors—PPARG—psoriasis	5.54e-05	0.00443	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	5.48e-05	0.00438	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Nuclear Receptors—PPARG—psoriasis	5.45e-05	0.00437	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—IL13—psoriasis	5.18e-05	0.00415	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	5e-05	0.004	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—RUNX3—psoriasis	4.98e-05	0.00398	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Biological oxidations—CYP2S1—psoriasis	4.94e-05	0.00396	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	4.93e-05	0.00394	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	4.88e-05	0.0039	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—CD4—psoriasis	4.81e-05	0.00385	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4.75e-05	0.0038	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—IL10—psoriasis	4.74e-05	0.00379	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—TARS—psoriasis	4.73e-05	0.00379	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—IL10—psoriasis	4.67e-05	0.00374	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	4.65e-05	0.00372	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—IL4—psoriasis	4.61e-05	0.00369	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—IL4—psoriasis	4.54e-05	0.00363	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—FOXA1 transcription factor network—JUN—psoriasis	4.54e-05	0.00363	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Transcription factor regulation in adipogenesis—TNF—psoriasis	4.49e-05	0.00359	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	4.41e-05	0.00353	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Nuclear Receptor transcription pathway—PPARG—psoriasis	4.38e-05	0.0035	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	4.34e-05	0.00347	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Nuclear Receptor transcription pathway—PPARG—psoriasis	4.31e-05	0.00345	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.29e-05	0.00343	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	4.27e-05	0.00342	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	4.22e-05	0.00338	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	4.2e-05	0.00336	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—HLA-A—psoriasis	4.18e-05	0.00334	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—NOS2—psoriasis	4.17e-05	0.00333	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	4.15e-05	0.00332	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—HLA-A—psoriasis	4.11e-05	0.00329	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Biological oxidations—CYP2S1—psoriasis	4.02e-05	0.00322	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—IL4—psoriasis	4e-05	0.0032	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	3.97e-05	0.00318	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL13—psoriasis	3.93e-05	0.00315	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of Androgen receptor activity—JUN—psoriasis	3.91e-05	0.00313	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	3.72e-05	0.00298	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—LEP—psoriasis	3.69e-05	0.00295	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Transcription factor regulation in adipogenesis—IL6—psoriasis	3.62e-05	0.0029	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—TARS—psoriasis	3.61e-05	0.00289	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—NDUFA5—psoriasis	3.54e-05	0.00283	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—FOXA1 transcription factor network—JUN—psoriasis	3.49e-05	0.0028	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.3e-05	0.00264	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.25e-05	0.0026	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—IL10—psoriasis	3.24e-05	0.00259	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—IFNG—psoriasis	3.2e-05	0.00256	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.19e-05	0.00255	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—ICAM1—psoriasis	3.18e-05	0.00254	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—SOCS1—psoriasis	3.17e-05	0.00254	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—CARM1—psoriasis	3.09e-05	0.00248	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	3.02e-05	0.00242	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CYP2S1—psoriasis	3.01e-05	0.00241	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.99e-05	0.00239	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—CARM1—psoriasis	2.97e-05	0.00238	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—CXCL8—psoriasis	2.97e-05	0.00238	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of Androgen receptor activity—JUN—psoriasis	2.96e-05	0.00237	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.95e-05	0.00236	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—IFNG—psoriasis	2.85e-05	0.00228	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.83e-05	0.00227	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	2.81e-05	0.00225	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—IFNG—psoriasis	2.79e-05	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	2.78e-05	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HCAR2—psoriasis	2.78e-05	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.78e-05	0.00222	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—TARS—psoriasis	2.78e-05	0.00222	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	2.77e-05	0.00222	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—JUN—psoriasis	2.76e-05	0.00221	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—IFNG—psoriasis	2.75e-05	0.0022	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—TARS—psoriasis	2.74e-05	0.00219	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—TYK2—psoriasis	2.73e-05	0.00218	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—CYP2S1—psoriasis	2.65e-05	0.00212	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	2.62e-05	0.00209	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CXCL8—psoriasis	2.59e-05	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	2.59e-05	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—JUN—psoriasis	2.58e-05	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CXCL8—psoriasis	2.55e-05	0.00204	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.52e-05	0.00202	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.52e-05	0.00201	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—JUN—psoriasis	2.47e-05	0.00197	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL10—psoriasis	2.46e-05	0.00197	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—IFNG—psoriasis	2.42e-05	0.00194	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TAGAP—psoriasis	2.41e-05	0.00193	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—JUN—psoriasis	2.41e-05	0.00193	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—NFKB1—psoriasis	2.37e-05	0.0019	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—JUN—psoriasis	2.37e-05	0.0019	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—CARM1—psoriasis	2.36e-05	0.00189	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—TP53—psoriasis	2.35e-05	0.00188	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—LEP—psoriasis	2.34e-05	0.00187	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Tryptophan metabolism—CAT—psoriasis	2.29e-05	0.00183	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—psoriasis	2.25e-05	0.0018	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—STAT3—psoriasis	2.23e-05	0.00179	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—NFKB1—psoriasis	2.2e-05	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HCAR2—psoriasis	2.19e-05	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	2.14e-05	0.00172	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.11e-05	0.00169	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	2.11e-05	0.00169	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—JUN—psoriasis	2.09e-05	0.00167	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—PPARG—psoriasis	2.04e-05	0.00163	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—NFKB1—psoriasis	2.01e-05	0.00161	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.97e-05	0.00158	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—STAT3—psoriasis	1.97e-05	0.00158	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.94e-05	0.00155	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TAGAP—psoriasis	1.9e-05	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—VDR—psoriasis	1.85e-05	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—CAT—psoriasis	1.83e-05	0.00146	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—CARM1—psoriasis	1.82e-05	0.00145	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—CARM1—psoriasis	1.79e-05	0.00143	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	1.77e-05	0.00142	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	1.69e-05	0.00135	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—IL6—psoriasis	1.67e-05	0.00134	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—JUN—psoriasis	1.65e-05	0.00132	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.63e-05	0.0013	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	1.63e-05	0.0013	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—TYK2—psoriasis	1.6e-05	0.00128	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TP53—psoriasis	1.59e-05	0.00127	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	1.59e-05	0.00127	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.58e-05	0.00126	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TP53—psoriasis	1.57e-05	0.00125	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—CARM1—psoriasis	1.49e-05	0.00119	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	1.48e-05	0.00118	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CARM1—psoriasis	1.47e-05	0.00118	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—IL6—psoriasis	1.46e-05	0.00117	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCL20—psoriasis	1.44e-05	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	1.44e-05	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—IL6—psoriasis	1.43e-05	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—APOE—psoriasis	1.42e-05	0.00114	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—VDR—psoriasis	1.41e-05	0.00113	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.4e-05	0.00112	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—psoriasis	1.38e-05	0.0011	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.37e-05	0.0011	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.35e-05	0.00108	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CXCL8—psoriasis	1.34e-05	0.00108	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—IL6—psoriasis	1.33e-05	0.00107	CbGpPWpGaD
Medroxyprogesterone Acetate—Abdominal pain—Cyclosporine—psoriasis	1.31e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Cyclosporine—psoriasis	1.31e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Dexamethasone—psoriasis	1.31e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Betamethasone—psoriasis	1.31e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Mycophenolic acid—psoriasis	1.3e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—JUN—psoriasis	1.3e-05	0.00104	CbGpPWpGaD
Medroxyprogesterone Acetate—Discomfort—Dexamethasone—psoriasis	1.3e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Betamethasone—psoriasis	1.3e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Hydrocortisone—psoriasis	1.3e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Methotrexate—psoriasis	1.3e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Mycophenolic acid—psoriasis	1.29e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Mycophenolic acid—psoriasis	1.29e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Methotrexate—psoriasis	1.29e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Methotrexate—psoriasis	1.29e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—PPARG—psoriasis	1.29e-05	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HCAR2—psoriasis	1.29e-05	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Mycophenolate mofetil—psoriasis	1.29e-05	0.000197	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Mycophenolic acid—psoriasis	1.29e-05	0.000197	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Hydrocortisone—psoriasis	1.28e-05	0.000197	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Methotrexate—psoriasis	1.28e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Mycophenolate mofetil—psoriasis	1.28e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Mycophenolate mofetil—psoriasis	1.28e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Methotrexate—psoriasis	1.28e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Hydrocortisone—psoriasis	1.27e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Hydrocortisone—psoriasis	1.27e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Methotrexate—psoriasis	1.27e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Triamcinolone—psoriasis	1.27e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—IL6—psoriasis	1.26e-05	0.00101	CbGpPWpGaD
Medroxyprogesterone Acetate—Oedema—Dexamethasone—psoriasis	1.26e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Dexamethasone—psoriasis	1.26e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Betamethasone—psoriasis	1.26e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Betamethasone—psoriasis	1.26e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Triamcinolone—psoriasis	1.26e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	1.25e-05	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—Infection—Dexamethasone—psoriasis	1.25e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Betamethasone—psoriasis	1.25e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—STAT3—psoriasis	1.25e-05	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—JUN—psoriasis	1.25e-05	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—Ill-defined disorder—Prednisone—psoriasis	1.25e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Triamcinolone—psoriasis	1.25e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Prednisolone—psoriasis	1.25e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Methotrexate—psoriasis	1.24e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Prednisone—psoriasis	1.24e-05	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Betamethasone—psoriasis	1.24e-05	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Dexamethasone—psoriasis	1.24e-05	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Triamcinolone—psoriasis	1.24e-05	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PPARG—psoriasis	1.24e-05	0.000991	CbGpPWpGaD
Medroxyprogesterone Acetate—Nervous system disorder—Betamethasone—psoriasis	1.24e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Dexamethasone—psoriasis	1.24e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Prednisone—psoriasis	1.24e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Betamethasone—psoriasis	1.23e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Dexamethasone—psoriasis	1.23e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—TNF—psoriasis	1.23e-05	0.000987	CbGpPWpGaD
Medroxyprogesterone Acetate—Tachycardia—Dexamethasone—psoriasis	1.23e-05	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Betamethasone—psoriasis	1.23e-05	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—Angioedema—Prednisone—psoriasis	1.23e-05	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.22e-05	0.00098	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Cyclosporine—psoriasis	1.22e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Triamcinolone—psoriasis	1.22e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Methotrexate—psoriasis	1.22e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mycophenolic acid—psoriasis	1.22e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Dexamethasone—psoriasis	1.22e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Betamethasone—psoriasis	1.22e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Hydrocortisone—psoriasis	1.22e-05	0.000186	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Prednisone—psoriasis	1.21e-05	0.000186	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Prednisone—psoriasis	1.21e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Methotrexate—psoriasis	1.21e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Hydrocortisone—psoriasis	1.21e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Prednisone—psoriasis	1.21e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Methotrexate—psoriasis	1.2e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—NFKB1—psoriasis	1.2e-05	0.000963	CbGpPWpGaD
Medroxyprogesterone Acetate—Anorexia—Betamethasone—psoriasis	1.2e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Dexamethasone—psoriasis	1.2e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Prednisolone—psoriasis	1.2e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Methotrexate—psoriasis	1.2e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Triamcinolone—psoriasis	1.2e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Mycophenolate mofetil—psoriasis	1.19e-05	0.000183	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Cyclosporine—psoriasis	1.19e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Prednisone—psoriasis	1.18e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Betamethasone—psoriasis	1.18e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Dexamethasone—psoriasis	1.18e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Cyclosporine—psoriasis	1.17e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Hydrocortisone—psoriasis	1.17e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Methotrexate—psoriasis	1.17e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Methotrexate—psoriasis	1.17e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Hydrocortisone—psoriasis	1.17e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Hydrocortisone—psoriasis	1.17e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Prednisone—psoriasis	1.17e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Methotrexate—psoriasis	1.16e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Mycophenolate mofetil—psoriasis	1.16e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Methotrexate—psoriasis	1.16e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Betamethasone—psoriasis	1.15e-05	0.000176	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Dexamethasone—psoriasis	1.15e-05	0.000176	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Mycophenolate mofetil—psoriasis	1.15e-05	0.000176	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Prednisone—psoriasis	1.15e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Prednisone—psoriasis	1.15e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Triamcinolone—psoriasis	1.14e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Prednisone—psoriasis	1.14e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Methotrexate—psoriasis	1.14e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Dexamethasone—psoriasis	1.14e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Betamethasone—psoriasis	1.14e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCL20—psoriasis	1.14e-05	0.000912	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	1.14e-05	0.000911	CbGpPWpGaD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	1.14e-05	0.000174	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Cyclosporine—psoriasis	1.14e-05	0.000174	CcSEcCtD
Medroxyprogesterone Acetate—AR—Gene Expression—CARM1—psoriasis	1.14e-05	0.000908	CbGpPWpGaD
Medroxyprogesterone Acetate—Paraesthesia—Dexamethasone—psoriasis	1.13e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Betamethasone—psoriasis	1.13e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Prednisone—psoriasis	1.13e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Methotrexate—psoriasis	1.13e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Methotrexate—psoriasis	1.12e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Methotrexate—psoriasis	1.12e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	1.12e-05	0.000893	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TAGAP—psoriasis	1.12e-05	0.000893	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Prednisolone—psoriasis	1.11e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Dexamethasone—psoriasis	1.11e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Betamethasone—psoriasis	1.11e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Mycophenolate mofetil—psoriasis	1.11e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Triamcinolone—psoriasis	1.1e-05	0.000169	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—psoriasis	1.1e-05	0.000169	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Triamcinolone—psoriasis	1.1e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Cyclosporine—psoriasis	1.1e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Prednisone—psoriasis	1.1e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Prednisone—psoriasis	1.1e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Betamethasone—psoriasis	1.1e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Dexamethasone—psoriasis	1.1e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—VEGFA—psoriasis	1.09e-05	0.000874	CbGpPWpGaD
Medroxyprogesterone Acetate—Infection—Prednisone—psoriasis	1.09e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Dexamethasone—psoriasis	1.09e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Betamethasone—psoriasis	1.09e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—psoriasis	1.09e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Hydrocortisone—psoriasis	1.09e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Betamethasone—psoriasis	1.09e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Dexamethasone—psoriasis	1.09e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—VDR—psoriasis	1.08e-05	0.000868	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—TNF—psoriasis	1.08e-05	0.000867	CbGpPWpGaD
Medroxyprogesterone Acetate—Shock—Prednisone—psoriasis	1.08e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.08e-05	0.000864	CbGpPWpGaD
Medroxyprogesterone Acetate—Nervous system disorder—Prednisone—psoriasis	1.08e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Prednisone—psoriasis	1.07e-05	0.000164	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Mycophenolate mofetil—psoriasis	1.07e-05	0.000164	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—VDR—psoriasis	1.07e-05	0.000855	CbGpPWpGaD
Medroxyprogesterone Acetate—Skin disorder—Prednisone—psoriasis	1.07e-05	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Prednisone—psoriasis	1.06e-05	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Hydrocortisone—psoriasis	1.06e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Cyclosporine—psoriasis	1.06e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.05e-05	0.00084	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Cyclosporine—psoriasis	1.05e-05	0.00016	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Prednisone—psoriasis	1.05e-05	0.00016	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Cyclosporine—psoriasis	1.05e-05	0.00016	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Hydrocortisone—psoriasis	1.04e-05	0.00016	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—psoriasis	1.04e-05	0.00016	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Cyclosporine—psoriasis	1.04e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.04e-05	0.000832	CbGpPWpGaD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—psoriasis	1.04e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Betamethasone—psoriasis	1.04e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Dexamethasone—psoriasis	1.04e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Betamethasone—psoriasis	1.03e-05	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Dexamethasone—psoriasis	1.03e-05	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Mycophenolate mofetil—psoriasis	1.03e-05	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Triamcinolone—psoriasis	1.02e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Mycophenolate mofetil—psoriasis	1.02e-05	0.000156	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Mycophenolate mofetil—psoriasis	1.02e-05	0.000156	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Mycophenolate mofetil—psoriasis	1.01e-05	0.000155	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—psoriasis	1.01e-05	0.000155	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—psoriasis	1.01e-05	0.000155	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Hydrocortisone—psoriasis	1.01e-05	0.000155	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Dexamethasone—psoriasis	1e-05	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Betamethasone—psoriasis	1e-05	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Prednisone—psoriasis	1e-05	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Prednisolone—psoriasis	9.99e-06	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Triamcinolone—psoriasis	9.97e-06	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Betamethasone—psoriasis	9.97e-06	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Dexamethasone—psoriasis	9.97e-06	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Dexamethasone—psoriasis	9.97e-06	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Betamethasone—psoriasis	9.97e-06	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—IL6—psoriasis	9.96e-06	0.000797	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NDUFA5—psoriasis	9.94e-06	0.000796	CbGpPWpGaD
Medroxyprogesterone Acetate—Insomnia—Prednisone—psoriasis	9.93e-06	0.000152	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Cyclosporine—psoriasis	9.86e-06	0.000151	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Prednisone—psoriasis	9.86e-06	0.000151	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Triamcinolone—psoriasis	9.83e-06	0.000151	CcSEcCtD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—PPARG—psoriasis	9.81e-06	0.000785	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Hydrocortisone—psoriasis	9.76e-06	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—psoriasis	9.74e-06	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Prednisone—psoriasis	9.66e-06	0.000148	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mycophenolate mofetil—psoriasis	9.62e-06	0.000147	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—psoriasis	9.57e-06	0.000147	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—psoriasis	9.57e-06	0.000147	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—psoriasis	9.57e-06	0.000147	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Prednisone—psoriasis	9.54e-06	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Prednisolone—psoriasis	9.53e-06	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Prednisolone—psoriasis	9.52e-06	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.51e-06	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Prednisone—psoriasis	9.47e-06	0.000145	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Prednisolone—psoriasis	9.46e-06	0.000145	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—psoriasis	9.46e-06	0.000145	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.43e-06	0.000755	CbGpPWpGaD
Medroxyprogesterone Acetate—Constipation—Prednisone—psoriasis	9.39e-06	0.000144	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Hydrocortisone—psoriasis	9.38e-06	0.000144	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—TNF—psoriasis	9.36e-06	0.000749	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Hydrocortisone—psoriasis	9.3e-06	0.000143	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Hydrocortisone—psoriasis	9.3e-06	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.27e-06	0.000742	CbGpPWpGaD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—psoriasis	9.25e-06	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	9.25e-06	0.00074	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Hydrocortisone—psoriasis	9.24e-06	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Triamcinolone—psoriasis	9.19e-06	0.000141	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—psoriasis	9.18e-06	0.000141	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Methotrexate—psoriasis	9.12e-06	0.00014	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Prednisone—psoriasis	9.05e-06	0.000139	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Dexamethasone—psoriasis	9.05e-06	0.000139	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Betamethasone—psoriasis	9.05e-06	0.000139	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CAT—psoriasis	9.03e-06	0.000723	CbGpPWpGaD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—psoriasis	9e-06	0.000138	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—psoriasis	8.98e-06	0.000138	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—HLA-A—psoriasis	8.98e-06	0.000718	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal pain—Prednisone—psoriasis	8.98e-06	0.000138	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Prednisolone—psoriasis	8.97e-06	0.000137	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Dexamethasone—psoriasis	8.92e-06	0.000137	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Betamethasone—psoriasis	8.92e-06	0.000137	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—psoriasis	8.91e-06	0.000137	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Gene Expression—VDR—psoriasis	8.9e-06	0.000712	CbGpPWpGaD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—psoriasis	8.87e-06	0.000136	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Triamcinolone—psoriasis	8.83e-06	0.000135	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Hydrocortisone—psoriasis	8.76e-06	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Triamcinolone—psoriasis	8.76e-06	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Triamcinolone—psoriasis	8.75e-06	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—psoriasis	8.75e-06	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Gene Expression—CARM1—psoriasis	8.74e-06	0.0007	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—IL6—psoriasis	8.74e-06	0.000699	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Prednisone—psoriasis	8.72e-06	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Triamcinolone—psoriasis	8.7e-06	0.000133	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Prednisone—psoriasis	8.68e-06	0.000133	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Prednisone—psoriasis	8.68e-06	0.000133	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Dexamethasone—psoriasis	8.63e-06	0.000132	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Betamethasone—psoriasis	8.63e-06	0.000132	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—CARM1—psoriasis	8.61e-06	0.000689	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—psoriasis	8.6e-06	0.000688	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—psoriasis	8.57e-06	0.000131	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP2S1—psoriasis	8.46e-06	0.000677	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—APOE—psoriasis	8.38e-06	0.000671	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—psoriasis	8.36e-06	0.000128	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Dexamethasone—psoriasis	8.34e-06	0.000128	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Betamethasone—psoriasis	8.34e-06	0.000128	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—psoriasis	8.3e-06	0.000127	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Triamcinolone—psoriasis	8.25e-06	0.000126	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—psoriasis	8.24e-06	0.000126	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—psoriasis	8.18e-06	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—psoriasis	8.16e-06	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NDUFA5—psoriasis	8.09e-06	0.000648	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Prednisone—psoriasis	8.09e-06	0.000124	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.08e-06	0.000647	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—psoriasis	8.08e-06	0.000124	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Dexamethasone—psoriasis	8.02e-06	0.000123	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Betamethasone—psoriasis	8.02e-06	0.000123	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—psoriasis	7.98e-06	0.000122	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SOCS1—psoriasis	7.95e-06	0.000636	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Betamethasone—psoriasis	7.95e-06	0.000122	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Dexamethasone—psoriasis	7.95e-06	0.000122	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Betamethasone—psoriasis	7.94e-06	0.000122	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Dexamethasone—psoriasis	7.94e-06	0.000122	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—psoriasis	7.92e-06	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—psoriasis	7.91e-06	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Betamethasone—psoriasis	7.9e-06	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Dexamethasone—psoriasis	7.9e-06	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Prednisone—psoriasis	7.88e-06	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—IL6—psoriasis	7.83e-06	0.000627	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NOS2—psoriasis	7.81e-06	0.000625	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Prednisone—psoriasis	7.77e-06	0.000119	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—psoriasis	7.56e-06	0.000116	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—PPARG—psoriasis	7.56e-06	0.000605	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL6—psoriasis	7.55e-06	0.000604	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.55e-06	0.000604	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Prednisone—psoriasis	7.51e-06	0.000115	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—psoriasis	7.5e-06	0.000115	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Dexamethasone—psoriasis	7.49e-06	0.000115	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Betamethasone—psoriasis	7.49e-06	0.000115	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—PPARG—psoriasis	7.45e-06	0.000596	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—psoriasis	7.29e-06	0.000112	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Prednisone—psoriasis	7.26e-06	0.000111	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—psoriasis	7.25e-06	0.000111	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—psoriasis	7.25e-06	0.000111	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.13e-06	0.00057	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—APOE—psoriasis	7.02e-06	0.000562	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Prednisone—psoriasis	6.98e-06	0.000107	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Prednisone—psoriasis	6.92e-06	0.000106	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Prednisone—psoriasis	6.92e-06	0.000106	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP2S1—psoriasis	6.88e-06	0.000551	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Prednisone—psoriasis	6.88e-06	0.000105	CcSEcCtD
Medroxyprogesterone Acetate—AR—Gene Expression—VDR—psoriasis	6.78e-06	0.000542	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—psoriasis	6.76e-06	0.000104	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCL20—psoriasis	6.69e-06	0.000535	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—psoriasis	6.58e-06	0.000101	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Prednisone—psoriasis	6.52e-06	9.99e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—psoriasis	6.49e-06	9.95e-05	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—TYK2—psoriasis	6.4e-06	0.000512	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—psoriasis	6.28e-06	9.62e-05	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SOCS1—psoriasis	6.27e-06	0.000502	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—PPARG—psoriasis	6.2e-06	0.000496	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PPARG—psoriasis	6.11e-06	0.000489	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—psoriasis	6.07e-06	9.3e-05	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—LEP—psoriasis	5.87e-06	0.00047	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—APOE—psoriasis	5.87e-06	0.00047	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—psoriasis	5.83e-06	8.94e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—psoriasis	5.79e-06	8.86e-05	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—CD4—psoriasis	5.79e-06	0.000463	CbGpPWpGaD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—psoriasis	5.78e-06	8.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Methotrexate—psoriasis	5.75e-06	8.81e-05	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NFKBIA—psoriasis	5.47e-06	0.000438	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Methotrexate—psoriasis	5.45e-06	8.35e-05	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NDUFA5—psoriasis	5.34e-06	0.000427	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—VDR—psoriasis	5.22e-06	0.000418	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—VDR—psoriasis	5.14e-06	0.000411	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—PPARG—psoriasis	4.73e-06	0.000378	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—APOE—psoriasis	4.63e-06	0.00037	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—LEP—psoriasis	4.63e-06	0.00037	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2S1—psoriasis	4.54e-06	0.000363	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TYK2—psoriasis	4.48e-06	0.000358	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—STAT3—psoriasis	4.48e-06	0.000358	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.43e-06	0.000355	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NFKBIA—psoriasis	4.31e-06	0.000345	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CARM1—psoriasis	4.13e-06	0.00033	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CXCL8—psoriasis	3.9e-06	0.000312	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.86e-06	0.000309	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SOCS1—psoriasis	3.68e-06	0.000295	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PPARG—psoriasis	3.64e-06	0.000291	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—JUN—psoriasis	3.63e-06	0.00029	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.61e-06	0.000289	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PPARG—psoriasis	3.58e-06	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TYK2—psoriasis	3.53e-06	0.000283	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NFKB1—psoriasis	3.49e-06	0.000279	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CARM1—psoriasis	3.36e-06	0.000269	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—psoriasis	3.17e-06	0.000253	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.14e-06	0.000251	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STAT3—psoriasis	3.14e-06	0.000251	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6—psoriasis	3.13e-06	0.00025	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCL8—psoriasis	3.08e-06	0.000246	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—JUN—psoriasis	2.86e-06	0.000229	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NFKB1—psoriasis	2.75e-06	0.00022	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—LEP—psoriasis	2.72e-06	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—APOE—psoriasis	2.72e-06	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CAT—psoriasis	2.54e-06	0.000203	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NFKBIA—psoriasis	2.53e-06	0.000203	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—psoriasis	2.5e-06	0.0002	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STAT3—psoriasis	2.47e-06	0.000198	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—psoriasis	2.39e-06	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CARM1—psoriasis	2.22e-06	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6—psoriasis	2.19e-06	0.000175	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TYK2—psoriasis	2.07e-06	0.000166	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CAT—psoriasis	2.07e-06	0.000165	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—APOE—psoriasis	1.97e-06	0.000158	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—psoriasis	1.89e-06	0.000151	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCL8—psoriasis	1.81e-06	0.000144	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6—psoriasis	1.73e-06	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPARG—psoriasis	1.72e-06	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JUN—psoriasis	1.68e-06	0.000134	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NFKB1—psoriasis	1.62e-06	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—APOE—psoriasis	1.61e-06	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—psoriasis	1.47e-06	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STAT3—psoriasis	1.45e-06	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPARG—psoriasis	1.4e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CAT—psoriasis	1.36e-06	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—psoriasis	1.11e-06	8.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—APOE—psoriasis	1.06e-06	8.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6—psoriasis	1.01e-06	8.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPARG—psoriasis	9.23e-07	7.38e-05	CbGpPWpGaD
